

Exactus, Inc.

09:30 26 May 2020

Exactus says strong 2019 sees it building foundation to become an industry leader

Exactus Inc (OTCMKTS:EXDI), the healthcare group which farms and manufactures hemp-derived cannabidiol (CBD) products, said 2019 saw it build the foundation to become an industry leader.

"2019 was a transformational year for Exactus as we entered into the hemp market in January," Emiliano Aloï, Exactus president said in a statement accompanying the firm's results for the year to December 30, 2019.

READ: Exactus promotes Derek Du Chesne to president; appoints to board of directors

"We completed our first harvest which is currently being processed into raw ingredients and have entered into multiple supply agreements with industry leaders in anticipation of additional supply as we are confident in our build out of the sales and marketing team," Aloï added.

Entering the hemp market early in 2019 meant the group posted revenue for the year of C\$345,680 versus zero in 2018, while the net loss was around C\$10.2 million from a loss of around C\$4.3 million the previous year as expenditure inevitably increased.

Exactus said it expects gross margins to improve as it begins using lower-cost inventory from its fall harvest.

Looking ahead, the group noted that, during the first quarter of this year, it received purchase orders for around C\$900,000 of CBD and CBG products.

"We now have the components in place to execute our long-term strategy and are looking forward to growing off of the foundation that we have established," the group added.

Shareholders' equity increased to C\$3.7 million in calendar 2019 from a shareholder deficit of C\$3.4 million in 2018.

Contact the author at giles@proactiveinvestors.com

Price: 0.08

Market Cap: \$4.26 m

1 Year Share Price Graph



November 2019 May 2020 November 20

Share Information

Code: EXDI

Listing: OTCQB

52 week	High	Low
	0.8	0.04

Sector: Pharma & Biotech

Website: www.exactusinc.com

Company Synopsis:

Exactus, Inc. , is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Exactus, Inc. named herein, including the promotion by the Company of Exactus, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).